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William D. Murrell, MD, Adam W. Anz, MD, Humeira Badsha, MD,
William F. Bennett, MD, Robert E. Boykin, MD, Arnold I. Caplan, PhDAbstractIn orthopedic surgery there has been a never-ending quest to improve surgical outcome and the patient’s experience. Pro-
gression has been marked by the refinement of surgical techniques and instruments and later by enhanced diagnostic imaging
capability, specifically magnetic resonance. Over time implant optimization was achieved, along with the development of
innovative minimally invasive arthroscopic technical skills to leverage new versions of classic procedures and implants to improve
short-term patient morbidity and initial, mid-term, and long-term patient outcomes. The use of regenerative and/or biological
adjuncts to aid the healing process has followed in the drive for continual improvement, and major breakthroughs in basic science
have significantly unraveled the mechanisms of key healing and regenerative pathways. A wide spectrum of primary and com-
plementary regenerative treatments is becoming increasingly available, including blood-derived preparations, growth factors,
bone marrow preparations, and stem cells. This is a new era in the application of biologically active material, and it is trans-
forming clinical practice by providing effective supportive treatments either at the time of the index procedure or during the
postoperative period. Regenerative treatments are currently in active use to enhance many areas of orthopedic surgery in an
attempt to improve success and outcome. In this review we provide a comprehensive overview of the peer-reviewed evidence-
based literature, highlighting the clinical outcomes in humans both with preclinical data and human clinical trials involving
regenerative preparations within the areas of rotator cuff, meniscus, ligament, and articular cartilage surgical repair.Introduction
Regenerative adjunctive treatment is the next logical
step in the progression of surgical intervention. Biolog-
ically augmented or regenerative techniques are at the
very forefront of modern treatment and have the po-
tential to transform the practice of medicine and sur-
gery significantly in a very short period. Less than 20
years ago, one of the first applications of platelet-rich
growth factors was successfully used to help augment
dental implantation [1]. From this starting point pro-
gressive advancements have been made, but much re-
mains to be learned. Although the basic science remains
in its infancy, especially in the areas of signaling,
regulation, and mechanism, regenerative knowledge
has expanded significantly in volume and across disci-
plines. The purpose of this review is to provide a road
map of the significant developments in preclinical and
clinical results involving biological solutions to improve1934-1482 ª 2015 by the American Academy of Physical Medicine and Reh
http://dx.doi.org/10.1016/j.pmrj.2015.01.015rotator cuff, ligament, meniscus, and articular cartilage
surgical repair.
DiscussionMethodologySearches via PubMed (through August 15, 2014) and
Google Scholar (through August 15, 2014) were per-
formed to identify both scientific investigations and
review articles to ensure inclusion of pertinent data.
Key words used included platelet-rich plasma (PRP),
mesenchymal stem cell (MSC), stem cell, growth factor,
basic science, cell signaling, paracrine, autocrine,
anterior cruciate ligament (ACL), rotator cuff,
meniscus, and cartilage. The articles were downloaded
directly from publishers or other online resources when
they were not available from the local medical library
and/or through interlibrary loan. The articles were thenabilitation  Open access under CC BY-NC-ND license.
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marily, the methodology and results were extracted
from each pertinent scientific article and categorized as
either preclinical or clinical data and presented in the
respective section.Basic Science
Background
Orthopedic surgery and therapeutics have come a
long way since the time of Aristotle, when the use of
bone marrow for restorative procedures was described.
Connolly and others [2-4] initiated the modern era of
evidence-based medicine regarding the role of bone
marrow in surgical treatments such as bone fracture
reconstruction. Indeed, needle aspiration of the iliac
crest to obtain autologous bone and marrow, especially
for spinal fusions, became a standard procedure in the
1980s [5,6]. This later understanding that marrow could
stimulate or add value to osteogenic reconstruction and
the popularity of bone marrow transplantation for the
past 50 years [7] has resulted in further scientific
exploration into the cellular basis of marrow’s thera-
peutic properties.
Based on this research, it has been proposed that
bone marrow aspirate (BMA) contains multipotent pro-
genitors, which Caplan [8] has named MSCs, as pictured
in Figure 1. It should be emphasized that the under-
standing in the late 1980s and early 1990s was that
adults had only one stem cell in marrow, the hemato-
poietic stem cell. Furthermore, the scientific commu-
nity maintained that individuals were born with the
requisite number of specific organ-specific cells (say,
cardiac myocytes) and that those cells became bigger or
smaller but did not increase in number [9].
The current scientific evidence has now provided
evidence that every tissue in the body has tissue-
specific progenitors and that MSCs are derived, totally
or in part, from perivascular cells called pericytes
[10-12]. Thus muscle has satellite cells (myogenic pro-
genitors) and a separate yet distinctive class of MSCs
that reside as functional pericytes in uninjured muscle,
and tendons have tendon progenitors and pericyte-
derived MSCs. The MSCs from bone marrow, muscle,
and tendon have the same general properties, but their
basic chemistries are quite different as controlled by
both their tissue of origin and the genome of the donor.
PRP
Platelets are small non-nucleated bodies in periph-
eral blood that are involved in hemostasis. Platelets
contain a number of proteins, cytokines, and other
bioactive factors that regulate wound healing. Plasma is
the fluid portion of blood and contains clotting factors,
proteins, and ions. Several authors have suggested that
the definition of PRP should include preparations that
have a platelet concentration of at least 1 millionplatelets per microliter and a 3- to 5-fold increase in
growth factor concentration and cytokines. Prepara-
tions of this composition have been associated with the
enhancement of healing [13,14].
The basic cytokines from the alpha granules of
platelets include transforming growth factoreb (TGF-b),
platelet-derived growth factor (PDGF), insulin-like
growth factor I and II, fibroblast growth factor,
epidermal growth factor, vascular endothelial growth
factor (VEGF), and endothelial growth factor. These
growth factors have important regulatory effects on
MSCs [15,16].
Bioactive factors are also found in the dense granules
in platelets, including serotonin, histamine, dopamine,
calcium, and adenosine. These nonegrowth factors
affect aspects of wound healing such as inflammation
proliferation and remodeling [17].
The platelets in PRP can be delivered in a clot that
contains adhesion molecules such as fibronectin, fibrin,
and vitronectin [18].MSCs
Bone marrow MSCs can be isolated and expanded in
culture [19,20]. These MSCs are a heterogeneous
mixture of cells that have at least 2 different capabil-
ities. Some of these cells are already committed to the
osteogenic pathway and accelerate bone formation and
regenerative repair [2-4,21,22], whereas other MSCs
have the capacity to be immunomodulatory and trophic
[23]. These MSCs are formed at broken and inflamed
blood vessels where the local pericyte detaches from
the vessel and becomes an activated MSC. This in situ
MSC secretes a curtain of bioactive agents that locally
inhibit the overaggressive immune system from sending
in integrating cells. This is the body’s first line of control
and defense against establishing an autoimmune reac-
tion against the antigens exposed by the injured tissue.
This immunomodulatory capacity of MSCs can be
harnessed to provide therapeutic effects against graft-
versus-host disease, Crohn disease with its inflamma-
tion of the gastrointestinal tract, and a large array of
other clinical situations (for more information, search
for “mesenchymal stem cells” at clinicaltrials.gov).
The “trophic” effects of MSCs establish a regener-
ative microenvironment at the site of injury by (1)
inhibiting ischemia-related apoptosis, (2) inhibiting
scar formation, (3) stimulating angiogenesis by
secreting large amounts of VEGF and by transforming
some of the MSCs back into pericytes that function to
stabilize the fragile, newly forming capillaries, and (4)
secreting tissue progenitor-specific mitogens so that
the slow process of tissue regeneration is enhanced
[24]. Thus MSCs serve as “drug stores” [25] for sites of
injury and/or inflammation by providing an array of
bioactive molecules tailored for that site and the
injury (Figure 1) [25,26].
Figure 1. The mesengenic process was first envisioned in the late 1980s as a pathway for marrow mesenchymal stem cells (MSCs) to differentiate
into a number of mesodermal cell types that could contribute to the fabrication of bone, cartilage, and muscle [25,26]. It is now clear that MSCs
can be isolated from many tissues because they are derived from perivascular cells and pericytes.
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Adipose-derived MSCs can be derived from the ablu-
minal side of blood cells in fat. They lack the expression
of TGF-b type 1 receptor and have reduced expression
of bone morphogenetic protein (BMP)-2, BMP-4, and
BMP-6 when compared with bone marrowederived
MSCs, and hence supplementation of these factors is
needed for chondrogenic differentiation. BMP-6 stimu-
lates stronger chondrogenic differentiation compared
with TGF-b [27].
Peripheral Blood Stem Cells
Stem cells harvested from the peripheral blood after
mobilization have garnered recent attention for ortho-
pedic application. Immature monocytes are normally
present in low numbers in the bloodstream. Their
production and release into the peripheral circulation
can be increased with granulocyte colony-stimulating
factor analogues such as granulocyte colony-
stimulating factor. Once mobilized, these cells can be
harvested from the bloodstream through a process
called apheresis. The techniques of stimulation with a
mobilization agent and harvest with apheresis have
been used safely by hematology oncology professionals
for bone marrow transplantation for more than 20 years
[28]. These cells represent a heterogenous mixture with
markers indicating hematopoietic precursors andmesenchymal cell precursors [29]. The authors of some
studies utilizing cells collected through mobilization and
blood harvest have termed these cells peripheral blood
stem cells (PBSCs) [29-31]. Basic science study into the
properties of these cells has shown that they are similar
to embryonal stem cells in that they express transcrip-
tion factors specific to embryonal stem cells, have
proliferative potential, have the ability to differentiate
into a multitude of cell types, and are more immature
than bone marrowederived mesenchymal stem cells
[30]. In addition, when injected subcutaneously into
mice, these cells have been found to migrate to multi-
ple organs, integrate, and function as the surrounding
cells. Direct comparison of MSCs and PBSCs has illus-
trated the same potential with regard to proliferative
and trophic ability [30]. PBSC harvest through apheresis
can produce high numbers of cells [29]. Although the
site of harvest of stem cells does not appear to effect
multipotentiality, proliferative potential, or trophic
ability, it does affect cell availability and regulatory
constraints.
Management of Innate Regenerative Capacities
With the further understanding of the medicinal
signaling properties of MSCs [32], a new concept
involving the management of the patient’s own intrinsic
regenerative capacity has emerged. The current data
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dedicated and tissue-specific progenitors and thus the
capacity to regenerate. Therefore, by calculated
manipulation of the local MSCs, true scarless regenera-
tion can be achieved. For example, a torn meniscus or
rotator cuff has the potential to regenerate (and prob-
ably does so in young children because of their large
titers of MSCs and progenitors). By adding “extra” MSCs,
it is theoretically possible to regenerate these tissues.
The concept of MSC-mediated immune modulation and
trophic activities are the drivers behind the more than
425 clinical trials using MSCs for a large spectrum of
clinical conditions that are currently registered at
clinicaltrials.gov. The strategic issue is how to deliver
the MSCs in the right numbers to the right place at the
right time.
Medical Management of MSCs
The titers of MSCs at various tissue locations naturally
decrease with age, with rough estimates in marrow
showing a 10-fold decrease between birth and the teen
years and another 10-fold decrease into older ages [33].
This decrease is primarily due to decreases in vascular
density, which is not only the source of local MSCs but
also the cause of poor wound repair in older adults. With
this decrease in vascular density comes the issue of how
to medically manage local MSC levels at sites of injury.
One approach is to add autologous MSCs to the
vascular circulation because MSCs naturally locate and
function at sites of injury or inflammation. The MSCs will
dock at these sites, sense the local environment, and
react by secreting agents based on cell types at that
site (eg, bone versus brain). Alternately, mobilizing
and freeing MSCs from their tethers in the basement
membranes surrounding all blood vessels could also be
efficacious. PRP is a multicomponent cocktail that,
when introduced into a vascularized tissue of a joint
space, not only assists in the detachment of MSCs from
their perivascular niche but also contains mitogens to
cause the newly released MSCs to replicate themselves,
increasing their local titers [34]. Thus, by increasing
local MSCs, we would expect an enhanced regeneration
of injured or surgically treated tissues.
Source of MSCs
If all MSCs are derived from pericytes [10-12], it fol-
lows that MSCs could be derived from any vascularized
tissue. The best studied sources of MSCs are bone
marrow [19-24,32-35] and fat [36,37], although MSCs
also have been isolated from umbilical cord, placenta,
skin, and muscle. In this regard, if all MSCs secrete a
curtain of immune-modulatory agents, allogeneic MSCs
should likewise be as useful medically as autologous
MSCs. It is to be expected that MSCs from different
anatomic locations or from different allogenic donors
will have different intrinsic chemistries even though
they may all provide efficacious medical outcomes.Indeed, several companies have reported encouraging
clinical results using freshly isolated autologous MSCs
(eg, Cytori Therapeutics, Inc, Tissue Genesis, and Lip-
ogems International SRL) or culture-expanded alloge-
neic MSCs (eg, Mesoblast Ltd, Osiris Therapeutics, Inc,
Celgene Corp, Athersys Inc, and Pluristem Therapeutics,
Inc) from different donors. Clearly, the medical use of
MSCs is just beginning, but based on the very successful
use of marrow alone, MSC use in orthopedics will be at
the forefront of new regenerative medicine protocols.Rotator Cuff RepairRotator cuff tears, both partial and full thickness,
can be a debilitating source of pain and cause significant
shoulder dysfunction. Interestingly, in the 1990s,
decompression and not repair was the gold standard. It
is logical that surgically reattached tendons provided for
better function of the shoulder. Furthermore, as repair
of torn tendons has become the gold standard, one
would assume that all repairs heal. However, a review of
the literature shows that the failure rate of rotator cuff
repair as reported in some publications exceeds 50%.
It has become clear that the biology of the healing
needs to be addressed to augment the healing of tendon
to bone. The tendons attach to bone through a transi-
tional area of fibrocartilage and then Sharpey fibers. If a
substance could be added to the repair site to help
facilitate the reattachment, this technique could
potentially result in higher healing rates. In other sections
we have discussed the action of PRP and stem cells on
healing in general; in this section we will focus on pre-
clinical and clinical studies and the application of PRP
and/or stem cell augmentation to rotator cuff repairs.
Preclinical Studies
PRP has been shown to stimulate tendon stem cells to
differentiate into tenocytes and initiate collagen
extracellular matrix production [38,39]. Tenocyte pro-
liferation was shown to be significantly increased by the
addition of leukocyte-poor PRP compared with control
subjects, who received 2% phosphate-buffered saline
solution [PBS] or 10% PBS. No difference in the prolif-
eration of tenocytes was found when comparing all 3
PRP types [40]. Platelets are released at an injury site
by activation of collagen in a more sustained fashion
compared with activation by thrombin [41].
Rat rotator cuff tendons treated with PRP demon-
strated better collagen linear alignment than did ten-
dons of control subjects. Non-PRP groups had higher
failure strain at 7 days, PRP had higher failure strain at
21 days, PRP had higher fibroblastic response and
vascular response at each time interval, and PRP had
more linear-aligned fibers at 21 days (þ). These data
illustrate that with use of PRP, cautious progression of
rehabilitation is probably warranted during the first 3
weeks after surgery [42]. Beck et al [42] suggest that
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one could also interpret that a cautious rehabilitation
process for 3 weeks after surgery is prudent and that
PRP has positive effects beyond 3 weeks.
The application of bone marrowederived cells to
augment rotator cuff healing has also been studied.
Gulotta et al [43] used a rat model to compare cultured
MSCs contained in a fibrin carrier versus fibrin carrier
alone versus cultured MSCs alone. Results did not
demonstrate any difference between the 3 groups in
terms of collagen formation or strength of repair [43].
Clinical Studies
Meta-analysis regarding the efficacy of PRP in aug-
menting rotator cuff tear repair was carried out before
consensus of the definition of PRP was reached [44]. The
analysis highlighted lack of standardization in study
methodology, PRP preparation, and outcome measures.
Unfortunately, and as noted by the authors of the
review, this lack of standardization would likely result in
a comparison of heterogenous PRP type products and
would make any conclusion difficult to ascertain with
any level of certainty.
As part of orthopedic surgical integration, early pio-
neers set out to incorporate PRP into the repair of
rotator cuffs. Many of the early adopters used platelet-
rich fibrin matrix (PRFM). PRFM was naturally chosen
because the processing technique allowed for creation
of a clot of the PRFM, analogous to the fibrin clot pro-
cess used in meniscal repair in the 1980s, and sutures
could then be run through the material to help hold it in
place. This approach was helpful when arthroscopic
techniques were used because the PRFM clot could be
run down the suture into the rotator space between the
bone and the rotator cuff tendon (Figure 2).
Standardization of the surgical technique with PRFM
never evolved, although it was recommended that the
clot be placed between the tendon and the bone. The
number of clots, size of clots per torn area, and other
parameters differed among the early studies. The peer-
reviewed publications in orthopedic journals haveFigure 2. Arthroscopic photos showing platelet-rich fibrin matrix clots being
the clot just prior to placement between the tendon and the bone.consisted of a high number of PRFM repairs. Of the 5
studies, 80% showed no benefit to healing of the rotator
cuff tear [45-48]. Only a study by Barber et al [49]
showed a lower retear rate when PRFM was added to
rotator cuff repairs. The white pages from gravitational
platelet separation (GPS) studies suggest that the
platelet concentrations in PRFM may be close to base-
line blood, although the spinning algorithm may push
concentrations closer to 2 times baseline. All of the
aforementioned studies used PRFM, which may not have
had platelet concentrations much above baseline
(Figure 3). Antuna et al [50] prospectively evaluated the
application of platelet-rich fibrin in massive rotator cuff
tears with a minimum of 24 months follow-up and noted
that there was no difference in retear rate or subjective
outcome between groups. Recently, thrombin-activated
PRP obtained by apheresis that was used to augment
arthroscopic rotator cuff repair in a randomized,
controlled trial (RCT) of 2 groups of 27 patients did not
show any difference in ultimate clinical improvement or
the retear rate [51].
In contrast, other studies have showed benefits of PRP
in augmentation of rotator cuff repair. Randelli et al [52]
concluded that the addition of PRP decreased pain and
positively affected rotator cuff healing. Gumina et al
[53], who reported on 80 consecutive patients with large
tears that were treated arthroscopically with single row
repair, concluded that platelet leukocyte membrane
significantly improved repair integrity on the basis of
postoperative magnetic resonance imaging (MRI) but did
not demonstrate a superior functional outcome.
Theoretically, techniques that may result in an in-
crease in bone marrowederived MSCs at the rotator cuff
repair site could include performing a microfracture
around the rotator cuff repair footprint and/or the
addition of MSCs from exogenous sources, such as BMA
(locally or remotely). Recently, investigators have used
bone marrow aspirate concentrate (BMAC) and demon-
strated beneficial results. Ellera Gomes et al [54] re-
ported on traditional mini-open rotator cuff repair
augmented with BMAC in 14 patients; at 12 months,sutured and run down the arthroscopic cannula. The final photo shows
Figure 3. Early studies that showed the benefit of adding platelet-rich
plasma to rotator cuff tears. Only 25% were platelet-rich fibrin matrix
studies; the remainder had admixtures higher than 2.5 times baseline
platelet concentrations. PLT ¼ platelet; GSPIII ¼ gravitational platelet
separation III.
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determined by MRI [54]. Hernigou et al [55] compared
single-row rotator cuff tear with and without BMAC
adjuvant treatment with known quantitative dosing
with grading of repair by monthly ultrasound for 24
months and confirmed by MRI with a minimum 10-year
follow-up. The authors found that the rotator cuff
healed within 6 months in 100% of patients in the BMAC
group (45/45) and in only 67% of the control group
(30/45). The retear rate was lower in the BMAC group,
with 87% of repairs still intact (39/45), versus only 44%
in the control group (20/45) at a minimum of 10-year
follow-up [55].Ligament Repair/ReconstructionACL reconstruction (ACLR) and other ligament sur-
geries are increasing in the United States and are now
numbering more than 120,000 reconstructions per year
[56]. Although ACLR is able to improve symptoms and
function compared with preoperative function, when
comparisons are made with persons who have never had
an ACL injury, the results of surgery are not that
impressive [57]. Poor rate of return to play [58], repeat
rupture or contralateral rupture [59], and premature
progression of osteoarthritis (OA) are all legitimate
concerns [60] and have not been optimized with the
current level of treatment despite great improvements
in technique.
Regenerative therapies have the potential to improve
current surgical interventions in the area of ligament
reconstruction and/or repair in the following area(s):
improved graft incorporation and strengthening, gene
therapy, trophic induction, tissue engineering, and
microenvironment facilitation with cells or bioactive
factors to optimize, delay, or obviate premature pro-
gression of OA [61]. In this section, ACL repair and
reconstruction and techniques to augment surgical
repair without engineered materials will be discussed.Preclinical Studies
Although past efforts to repair torn ACLs failed, in-
terest has resurfaced in understanding the mechanisms
of this failure, healing in the synovial environment,
and unique biomechanical requirements for repairs to
succeed. Experiments comparing application of
different growth factors in animals with partial ACL
tears and ACL explant models demonstrated that
TGF-b1 might promote initial healing and overall healing
both histologically and biomechanically [62,63]. In
18 sheep undergoing ACL reconstruction, a VEGF-soaked
graft was compared with a control group. Although the
VEGF group demonstrated improved vascularization,
increased graft laxity and a weakened graft were found
at 12 weeks [64].
Partial ACL tears were treated in 2 separate rat
models by injecting MSCs (cultured and/or BMAC) into
the joints after surgical lesions were created. Both
studies demonstrated nearly normal strength and liga-
ment healing compared with control subjects [65,66].
For ACL reconstruction, comparable healing of auto-
graft and allograft ACLs was seen along with improved
strength with concomitant use of MSCs in a rabbit model
in 2 separate studies [67,68]. Lui et al [69] applied
tendon-derived stem cell sheets formed without a
scaffold in 97 rats undergoing ACL reconstruction; this
application resulted in higher tunnel bone mineral
density and bone volume, better graft osteointegration,
and higher intra-articular graft integrity with lower
cellularity, vascularity, and cell alignment compared
with the control group, but biomechanically no differ-
ence was found between groups [69]. Application of
cultured autologous synovium-derived cells with and
without fibrin-sealed TGF-b was performed at the time
of hamstring ACL reconstruction in 50 sheep divided
equally into 5 groups. This application resulted in no
necrotic deterioration in the mid-substance in the 3
intervention groups as was seen in the 2 control groups,
and biomechanically superior maximum load and
stiffness was found in the 2 groups treated with
synovium-derived cells and fibrin-sealed TGF-b [70].
Clinical Studies
Seijas et al [71] completed a retrospective review of
the rate of return to play in 19 professional soccer players
with partial ACL tears. All players were treated with
arthroscopically controlled 4-mL and 6-mL injections of
calcium chlorideeactivated PRP in the intact postero-
lateral bundle and intra-articularly, respectively. This
treatment resulted in KT-1000 normalization in all cases.
Eighteen of 19 players were able to return to their pre-
vious level of play at mean of 16.20 weeks [71].
Radice et al [72], in a prospective study of 100 ACL
reconstructions, divided subjects into 2 groups: group A
was treated with PRP gel (PRPG), and group B was a
control group. MRI demonstrated that it took 179 days to
complete graft homogeneity in group A compared with
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double-blind RCT in 100 patients undergoing allograft
patella ACL reconstruction, the intervention group was
given activated PRP; at 24-month follow-up, no differ-
ence was found in terms of subjective outcome,
biomechanical integration, or graft integration [73]. In a
prospective study of hamstring ACL reconstruction that
used grafts soaked with calcium chlorideeactivated PRP
in 36 subjects in the intervention group versus no PRP
treatment in 27 control subjects, when an evaluation
was performed by second-look arthroscopy and histol-
ogy, no difference in appearance was found. However,
histologically, newly formed connective tissue envel-
oping the graft was found in 77.3% of intervention
group versus 40% of control subjects [74]. In an RCT of
50 patients in 2 equal groups undergoing hamstring ACL
reconstruction, the intervention group received
thrombin-activated PRP-soaked grafts and demon-
strated improved anterior-posterior instrumented knee
stability via a KT 2000 arthrometer at 6 months [75].
Silva and Sampaio [76] prospectively evaluated graft-
tunnel healing in an anatomic ACL reconstruction
study in 40 patients sequentially divided into 4 groups:
group A, without PRP; group B, with PRP in the femoral
tunnels; group C, with PRP in the femoral tunnels and
intra-articularly; and group D, with thrombin-activated
PRP in the femoral tunnels. MRI completed at 3
months showed no difference between groups in terms
of bone-tunnel healing [76]. A randomized single-blind
prospective study compared the use of autologous
platelet concentrate in 30 patients (group A) versus a
control group of 20 patients (group B) undergoing
ACL reconstruction with hamstring grafts. At 6 months,
MRI evaluation was performed and no difference was
found in graft integration, bone tunnel healing, or
maturation [77].
A single study has investigated the use of BMSCs in
ACL reconstruction in humans. A prospective random-
ized study was performed with 43 patients divided into a
control group of 23 patients and an intervention group
of 20 patients who received BMAC. All 43 patients
underwent ACL reconstruction with hamstring grafts,
and in the intervention group, BMAC was injected within
and around the femoral side of the graft and inside the
femoral tunnels with the graft in place [78]. Unfortu-
nately, no characterization of the aspirate, viability, or
numeration was completed on any sample. MRI did not
detect any differences between groups, but no post-
operative time frame was reported.Meniscal Repair/RegenerationThe anatomy and vascular supply of the meniscus
cartilage of the knee has been well studied and docu-
mented [79]. Biomechanical and clinical data have
demonstrated the importance of the meniscus and of
meniscal preservation for protection of the articularcartilage, distribution of forces, and as a secondary
stabilizer [80]. Techniques for repair have evolved and
include inside-out, outside-in, and all-inside tech-
niques. Although fixation methods have improved, there
has been an increasing interest in biologic augmentation
of these repairs to enhance healing given the limited
blood supply. Based on data demonstrating increased
rates of meniscal healing when an ACL reconstruction
was performed (versus a repair in isolation) [81], which
potentially is thought to be due to the release of
marrow elements, marrow stimulation techniques have
been described [82]. Recent studies in a rabbit model
have shown improvements in the quality and quantity of
the reparative tissue bridging a meniscal repair when
using these marrow stimulation techniques [83]. This
improvement potentially is thought to be due to
increased release of growth factors, including platelet-
derived growth factor (PDGF) [84]. These advances
have resulted in a proliferation of research in the bio-
logic realm of the augmentation of meniscal repair.
Preclinical Studies
Multiple animal studies have examined the use of
biologic augmentation on meniscal repair. Initial data
from Arnoczky and Warren in dogs demonstrated the
ability to heal tears in the central portion of the
meniscus by creating vascular channels [85]. In addition
to increasing the vascular supply, growth factors
(including PDGF) have shown promise in both in vitro
and in vivo studies [86,87]. These data led to the theory
that PRP may be of utility in the augmentation of
meniscal healing. The scientific basis for this theory is
largely based on an article pertaining to a rabbit model,
which used a gelatin hydrogel scaffold that resulted in a
time-release elution of PRP over 4 weeks [88]. This
technique resulted in improved histologic scores at 12
weeks, leading to the hypothesis that PRP may be useful
in healing meniscal defects. A second study in a rabbit
model used a hyaluronan-collagen scaffold to deliver
PRP [89]. The results demonstrated no improvement
compared with the control group, which was noted both
in trials of PRP and BMA.
One study did investigate the use of BMA in a sheep
model for defects in the red-white zone of the meniscus
[90]. A significantly increased cell count, formation of
plaques, and neovascularization were found in the BMA
group without any difference seen in collagen fibril
formation. Autologous, marrow-derived stem cells have
been studied and were found to enhance repair in a
rabbit model [91]. Large meniscal defects were created
and filled with a hyaluronan-gelatin scaffold in one
knee; the other knee was used as a control. In the other
subgroup the defect was treated with autologous
marrow-derived MSCs loaded on a scaffold, with
the contralateral knee receiving a scaffold only. The
width of the regenerated tissue was significantly higher
in the knees treated with MSC, and integration with
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specimens in the MSC group versus 18% of the control
subjects that received a scaffold alone. Another study
using a 2-mm punch defect in a rabbit model examined
the use of MSCs that were precultured versus uncultured
cells [92]. The rabbits that received precultured MSCs
were found to have fibrocartilage-like repair tissue that
was partially integrated. The uncultured MSCs stimu-
lated the development of completely integrated
meniscus-like reparative tissue at 3 months, suggesting
that minimally manipulated cells lines may perform
better for this application. Allogenic MSCs have also
been tested in a massive meniscectomy model, created
by excising the anterior half of the medial meniscus
[92]. Two weeks later MSCs were injected in PBS and
compared with control subjects. The size of the
meniscus was larger at 4 and 12 weeks in the MSC group,
but no difference was seen at 16 and 24 months. How-
ever, histological scores were better in the MSC group
than in the control group at 1, 3, 4, and 6 months.
A punch defect model (1.5 mm in the avascular zone)
has also been tested with allogenic MSCs [93]. This study
also used a PBS and demonstrated that the quality of the
repair tissue was improved at all end points with MSCs
(reaching significance at 12 and 24 weeks), as was the
quantity (reaching significance at 4 and 12 weeks).
Clinical Studies
Currently, no controlled human studies have been
performed to evaluate the use of PRP, BMA, or MSCs in
the treatment of meniscal tears, and therefore the
human clinical evidence remains largely anecdotal.
A single double-blind RCT has been completed
using cultured allogenic MSC injections after partial
meniscectomy; it showed that 24% of patients in the
intervention group had increased meniscal volume
after the procedure [94]. Work in the area of meniscal
repair/regeneration is in its infancy clinically, but the
results of many current trials are forthcoming.Cartilage Repair
Preclinical Studies
Cartilage repair has long been an area of difficulty
within orthopedics. Animal studies investigating stem
cell therapy to improve methods of cartilage repair have
illustrated benefit and guided clinical development
[95-101]. A report of the initial investigation of stem
cells and cartilage repair was published in 1994 [101].
Investigators created a full-thickness defect in a rabbit
model, into which MSCs embedded in a collagen I gel
were placed. Serial histologic evaluation revealed that
the cells differentiated into chondrocytes in a uniform
fashion as soon as 2 weeks, and at 24 weeks a sub-
chondral bone layer was re-established [101]. Subse-
quent investigators have sought to further optimize the
implantation of cells for cartilage repair [95,101]. Thesestudies have suggested that allograft cells may be as
effective as autograft cells [100], differentiating a cell
to the chondrocyte lineage may not be advantageous,
and for cartilage integration and differentiation pur-
poses, a more immature cell is more effective [95].
Implantation at the time of surgery with a scaffold is
not the only method for cell application. Three studies
have illustrated improvement with application of stem
cells at a time point after marrow stimulation [97-99].
Lee et al [97] investigated 3 weekly injections of MSCs
suspended in 2 mL of hyaluronan after creation of a
cartilage defect in mini-pigs [97]. The cell-treated
group demonstrated improvement in histologic and
morphologic scores. Additionally, carboxyfluoroscein-
labeled MSCs were found at the base of the repair
cartilage, suggesting an innate, functional homing
mechanism of the cells [97]. A similar study evaluated
the effectiveness of one injection of bone mar-
rowederived MSCs 1 month after microfracture [98].
This study illustrated a trend toward overall improve-
ment, with significance achieved in repair tissue firm-
ness and aggrecan content [98]. These 3 studies suggest
that postoperative injections are effective in the
application of stem cells and that the timing of in-
jections and the number of cells applied is important.
Adipose-derived MSCs also have potential application
in cartilage regeneration and have been shown to have
superior proliferative potential compared with other
types of MSCs [102]. Within a rabbit model, adipose-
derived MSC applied in a fibrin glue scaffold illustrated
excellent rates of subchondral bone healing [96]. How-
ever, direct comparison of the chondrogenic potential
of adipose-derived and bone marrowederived cells has
illustrated a greater efficiency and quality of chondro-
genesis with bone marrowederived cells [102,103].
Because of regulatory restraints with isolated stem
cell populations, clinicians have also sought to augment
current cartilage repair techniques with bone marrow
aspirate. Authors of 2 animal studies have investigated
the addition of bone marrow aspirate to a common,
simple cartilage repair technique and found effective
results [98,99]. The first study involved augmentation of
subchondral drilling with postoperative injections of
BMA. Histologic scoring was best in the group that
received 3 postoperative injections of BMA and sodium
hyaluronate at week intervals compared with the group
with no postoperative injections and a group with
sodium hyaluronate injections alone [99]. A similar
study compared microfracture and BMA placed at the
site of microfracture in a horse model. The BMA group
scored higher in MRI, gross morphologic, and histologic
scores [98].
Clinical Studies
The clinical application of stem cells to cartilage
regeneration has 4 studies for evaluation, including 2
prospective observational cohort studies, a case series
S49W.D. Murrell et al. / PM R 7 (2015) S41-S52with histology, and a randomized controlled trial
[29,31,104,105]. The first observational cohort study
compared autologous chondrocyte implantation (ACI) in
36 patients with bone marrowederived MSC implanta-
tion in 36 patients [104]. No clinical difference was
found between the 2 groups at the 24-month time point.
A follow-up study investigated MSC implantation in an
open surgical fashion to postoperative injection of MSCs
after an arthroscopic surgery. The arthroscopic cohort
scored higher in subjective outcome scores [105]. PBSCs
have also been investigated clinically. An initial case
series utilizing PBSCs to augment arthroscopic sub-
chondral drilling illustrated morphologic and staining
properties on histology that approached natural carti-
lage [29]. This method has subsequently been investi-
gated in an RCT comparing clinical outcomes with
International Knee Documentation Committee scores at
18 months, morphology of repair with MRI, and repair
tissue quality with histologic biopsy [31]. The interven-
tion group underwent postoperative injections of PBSCs
and hyaluronan, whereas the control group underwent
injections of hyaluronan alone. Repair tissue as evalu-
ated with the International Cartilage Repair Society II
histologic score and an MRI morphologic score illus-
trated statistical superiority in the PBSC group. Clinical
outcome scores at 24 months did not illustrate a sta-
tistical difference [31].
Conclusion
It is clear from the known basic science that many of
the therapeutic benefits seen in the augmentation of
current surgical procedures are mediated by the acti-
vation or addition of MSCs or pericytes. The use of bone
marrowederived MSCs are most commonly reported in
the literature and in some investigations are demon-
strating promising early clinical results in the augmen-
tation of current surgical procedures. Use of stem cells
derived from adipose tissue, peripheral blood, and
umbilical blood are also being reported clinically.
Additional study of the use of PRP to augment rotator
cuff surgery is required at the basic science and clinical
levels. Additionally, standardization of preparations and
consensus among practitioners regarding the correct
constitution of PRP for specific uses requires elucidation.
A long-term clinical report has demonstrated the effec-
tiveness of BMAC augmentation to decrease failure rate
compared with control subjects. The administration of
BMAC should be considered as initial treatment after
known rotator cuff injury and could possibly reduce the
use of corticosteroids in rotator cuff syndrome/tendin-
opathy/impingement management in the future.
In both preclinical and clinical studies, ACL injury/
reconstruction with biologic augmentation has shown
positive results in limited investigations in the treat-
ment of partial ACL tear alone. Both PRP and BMA have
sufficient evidence to support their use in furtherclinical investigations for treatment of partial ACL
tears. To date, biologic augmentation of ACL recon-
struction has not shown any positive or harmful effect,
and further basic science investigation is warranted.
Based on existing data using PRP, BMAC, and MSCs,
early evidence is available for biologic augmentation of
meniscal repair for use in clinical investigation. Fibrin
clots have been used successfully for many years for
meniscal repair, and use of PRP is an improvement of
the technique. Additional research is necessary to fully
validate these treatments for meniscal disorders.
The use of biological augmentation of cartilage repair
techniques has good and evolving evidence regarding
the use of peripheral blood, BMAC, MSCs, and allogenic
cord blood to improve currently performed marrow
stimulating techniques with documented safety and
efficacy.
The use of biologics in the augmentation of current
surgical procedures has a promising future. Many in-
vestigators are hopeful that biologics or biologically
induced regeneration will some day supplant many of
the surgical reconstructive procedures currently being
performed today.References
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